A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.

@article{Wolf2004API,
  title={A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.},
  author={Judith K. Wolf and Diane C. Bodurka and Jacalyn B Gano and Michael T. Deavers and Lois Michelle Ramondetta and Pedro T Ramirez and Charles L Levenback and David M. Gershenson},
  journal={Gynecologic oncology},
  year={2004},
  volume={94 2},
  pages={442-8}
}
PURPOSE Adenoviral p53 (Adp53) is a replication-deficient adenovirus containing human p53 cDNA. This phase I study was designed as a toxicity study of multiple dosing of Adp53 administered by intraperitoneal (IP) delivery to patients with ovarian cancer. EXPERIMENTAL DESIGN Eligibility criteria included patients with platinum- and paclitaxel-resistant metastatic epithelial ovarian cancer; a Zubrod performance status of 0, 1, or 2; and adequate bone marrow, liver, and renal function. Patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…